Branford-based BioXcel Corporation reports the initiation of a big data project with Alexion to characterize and prioritize pertinent sets of rare diseases for relevant therapeutic modalities. “We are pleased to work with Alexion and utilize our expertise and experience to support the development of novel treatment options for patients with rare diseases,” said Vimal Mehta, Ph.D., CEO and chairman of BioXcel … more

Separately, Alexion reports that its board of directors has appointed David L. Hallal as the Company’s chief executive officer, effective April 1. Mr. Hallal currently serves as Alexion’s chief operating officer and is a director. He will succeed Leonard Bell, M.D., chairman and CEO, who will retire as CEO and continue to serve as chairman of the board. Dr. Bell was the principal founder of Alexion in 1992 and has served as CEO for the past 23 years … more